What is Quanta BioDesign?
Quanta BioDesign, Ltd., founded in 1997 and based in Powell, Ohio, is a biotechnology company specializing in the development and commercialization of proprietary discrete polyethylene glycol (dPEG®) chemistries. The company's unique single molecular weight ethylene glycol conjugation technology is designed to overcome common challenges in diagnostic and therapeutic product development, such as aggregation, poor water solubility, and short serum half-life. Quanta BioDesign's dPEG® platform offers a versatile technology that can be customized for a wide range of diagnostic and therapeutic applications, including conjugations, labeling, and peptide synthesis. The company's focus on advancing cross-linking and labeling chemistries aims to revolutionize existing approaches in therapeutic and diagnostic development.
How much funding has Quanta BioDesign raised?
Quanta BioDesign has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Quanta BioDesign
PPP
Public-Private Partnership
What's next for Quanta BioDesign?
With its recent strategic investment, Quanta BioDesign is poised to accelerate the commercialization of its advanced dPEG® technologies. The substantial capital infusion, part of a large-scale late-stage funding initiative, will likely support expanded research and development efforts, enhance manufacturing capabilities, and broaden market penetration. This strategic backing signals confidence in Quanta BioDesign's innovative platform and its potential to significantly impact the future of drug discovery and diagnostic tools.
See full Quanta BioDesign company page
